The effect of chronic twice daily exenatide treatment on β-cell function in new onset type 2 diabetes.

Gastaldelli A, Brodows RG, D'Alessio D

Clinical endocrinology11 Apr 2013Cited by 21 (Europe PMC)

PMID23574529DOI10.1111/cen.12199PepBankPUB-23574529

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study14

12 results from studies that gave the peptide. 12 results from people.

01HumanRandomized controlled trialEfficacy outcome
In adults with previously untreated type 2 diabetes, plasma insulin levels and unadjusted insulin secretion rates during the OGTT did not differ before or after 24 weeks of exenatide or placebo.
In plain wordsIn people with previously untreated type 2 diabetes, insulin levels and insulin secretion during glucose testing did not change with exenatide or placebo.
Peptide
Exenatide (exendin-4)
Outcome
No significant changeUnadjusted plasma insulin and insulin secretion rate during OGTT
Study
n = 79
Comparator
Placebo
Outcome group
Glycemic control · Metabolic and weight
Studied dose
5 or 10 μg twice daily · 24 weeksAs given in this study (human).
Source sentences
Summary
Plasma insulin levels and ISR during the OGTT did not differ before or after treatment with exenatide or placebo.
1 context sentence(design, population, supporting numbers)
Summary · context
Seventy-nine subjects with previously untreated T2DM were studied before and after 24 weeks of treatment with one of the two doses of exenatide, 5- or 10-μg twice daily, or placebo.
Report a problemFND-2357452911
02HumanRandomized controlled trialEfficacy outcome
In untreated diabetes, low-dose exenatide reduced HbA1c compared with placebo.
In plain wordsIn untreated diabetes, low-dose exenatide reduced HbA1c more than placebo.
Peptide
Exenatide (exendin-4)
Outcome
DecreaseHbA1c at low dose
Study
n: not reported in source
Comparator
Placebo
Outcome group
Glycemic control · Metabolic and weight
Studied dose
5 μg twice daily · 24 weeksAs given in this study (human).
Source sentences
Summary
Compared to placebo, 24 weeks of daily high- or low-dose exenatide treatment reduced HbA1c and improved fasting and postprandial hyperglycaemia.
1 context sentence(design, population, supporting numbers)
Summary · context
Seventy-nine subjects with previously untreated T2DM were studied before and after 24 weeks of treatment with one of the two doses of exenatide, 5- or 10-μg twice daily, or placebo.
Report a problemFND-2357452902
03HumanRandomized controlled trialEfficacy outcome
In untreated diabetes, high-dose exenatide reduced HbA1c compared with placebo.
In plain wordsIn untreated diabetes, high-dose exenatide reduced HbA1c more than placebo.
Peptide
Exenatide (exendin-4)
Outcome
DecreaseHbA1c at high dose
Study
n: not reported in source
Comparator
Placebo
Outcome group
Glycemic control · Metabolic and weight
Studied dose
10 μg twice daily · 24 weeksAs given in this study (human).
Source sentences
Summary
Compared to placebo, 24 weeks of daily high- or low-dose exenatide treatment reduced HbA1c and improved fasting and postprandial hyperglycaemia.
1 context sentence(design, population, supporting numbers)
Summary · context
Seventy-nine subjects with previously untreated T2DM were studied before and after 24 weeks of treatment with one of the two doses of exenatide, 5- or 10-μg twice daily, or placebo.
Report a problemFND-2357452903
04HumanRandomized controlled trialEfficacy outcome
In untreated diabetes, low-dose exenatide improved fasting hyperglycaemia compared with placebo.
In plain wordsIn untreated diabetes, low-dose exenatide reduced fasting blood sugar more than placebo.
Peptide
Exenatide (exendin-4)
Outcome
DecreaseFasting hyperglycaemia at low dose
Study
n: not reported in source
Comparator
Placebo
Outcome group
Glycemic control · Metabolic and weight
Studied dose
5 μg twice daily · 24 weeksAs given in this study (human).
Source sentences
Summary
Compared to placebo, 24 weeks of daily high- or low-dose exenatide treatment reduced HbA1c and improved fasting and postprandial hyperglycaemia.
1 context sentence(design, population, supporting numbers)
Summary · context
Seventy-nine subjects with previously untreated T2DM were studied before and after 24 weeks of treatment with one of the two doses of exenatide, 5- or 10-μg twice daily, or placebo.
Report a problemFND-2357452904
05HumanRandomized controlled trialEfficacy outcome
In untreated diabetes, high-dose exenatide improved fasting hyperglycaemia compared with placebo.
In plain wordsIn untreated diabetes, high-dose exenatide reduced fasting blood sugar more than placebo.
Peptide
Exenatide (exendin-4)
Outcome
DecreaseFasting hyperglycaemia at high dose
Study
n: not reported in source
Comparator
Placebo
Outcome group
Glycemic control · Metabolic and weight
Studied dose
10 μg twice daily · 24 weeksAs given in this study (human).
Source sentences
Summary
Compared to placebo, 24 weeks of daily high- or low-dose exenatide treatment reduced HbA1c and improved fasting and postprandial hyperglycaemia.
1 context sentence(design, population, supporting numbers)
Summary · context
Seventy-nine subjects with previously untreated T2DM were studied before and after 24 weeks of treatment with one of the two doses of exenatide, 5- or 10-μg twice daily, or placebo.
Report a problemFND-2357452905
06HumanRandomized controlled trialEfficacy outcome
In untreated diabetes, low-dose exenatide improved postprandial hyperglycaemia compared with placebo.
In plain wordsIn untreated diabetes, low-dose exenatide reduced blood sugar after meals more than placebo.
Peptide
Exenatide (exendin-4)
Outcome
DecreasePostprandial hyperglycaemia at low dose
Study
n: not reported in source
Comparator
Placebo
Outcome group
Glycemic control · Metabolic and weight
Studied dose
5 μg twice daily · 24 weeksAs given in this study (human).
Source sentences
Summary
Compared to placebo, 24 weeks of daily high- or low-dose exenatide treatment reduced HbA1c and improved fasting and postprandial hyperglycaemia.
1 context sentence(design, population, supporting numbers)
Summary · context
Seventy-nine subjects with previously untreated T2DM were studied before and after 24 weeks of treatment with one of the two doses of exenatide, 5- or 10-μg twice daily, or placebo.
Report a problemFND-2357452906
07HumanRandomized controlled trialEfficacy outcome
In untreated diabetes, high-dose exenatide improved postprandial hyperglycaemia compared with placebo.
In plain wordsIn untreated diabetes, high-dose exenatide reduced blood sugar after meals more than placebo.
Peptide
Exenatide (exendin-4)
Outcome
DecreasePostprandial hyperglycaemia at high dose
Study
n: not reported in source
Comparator
Placebo
Outcome group
Glycemic control · Metabolic and weight
Studied dose
10 μg twice daily · 24 weeksAs given in this study (human).
Source sentences
Summary
Compared to placebo, 24 weeks of daily high- or low-dose exenatide treatment reduced HbA1c and improved fasting and postprandial hyperglycaemia.
1 context sentence(design, population, supporting numbers)
Summary · context
Seventy-nine subjects with previously untreated T2DM were studied before and after 24 weeks of treatment with one of the two doses of exenatide, 5- or 10-μg twice daily, or placebo.
Report a problemFND-2357452907
08HumanRandomized controlled trialEfficacy outcome
In untreated diabetes, exenatide was associated with improved peripheral insulin sensitivity independent of weight change.
In plain wordsIn untreated diabetes, exenatide was linked to improved peripheral insulin sensitivity independent of weight change.
Peptide
Exenatide (exendin-4)
Outcome
IncreasePeripheral insulin sensitivity
Study
n: not reported in source
Outcome group
Glycemic control · Metabolic and weight
Studied dose
Dose not stated · 24 weeksAs given in this study (human).
Source sentences
Summary
Exenatide was associated with improved OGIS and Hep-IR independent of changes in weight.
1 context sentence(design, population, supporting numbers)
Summary · context
Seventy-nine subjects with previously untreated T2DM were studied before and after 24 weeks of treatment with one of the two doses of exenatide, 5- or 10-μg twice daily, or placebo.
Report a problemFND-2357452908
09HumanRandomized controlled trialEfficacy outcome
In untreated diabetes, exenatide was associated with improved hepatic insulin resistance independent of weight change.
In plain wordsIn untreated diabetes, exenatide was linked to improved liver insulin resistance independent of weight change.
Peptide
Exenatide (exendin-4)
Outcome
DecreaseHepatic insulin resistance
Study
n: not reported in source
Outcome group
Glycemic control · Metabolic and weight
Studied dose
Dose not stated · 24 weeksAs given in this study (human).
Source sentences
Summary
Exenatide was associated with improved OGIS and Hep-IR independent of changes in weight.
1 context sentence(design, population, supporting numbers)
Summary · context
Seventy-nine subjects with previously untreated T2DM were studied before and after 24 weeks of treatment with one of the two doses of exenatide, 5- or 10-μg twice daily, or placebo.
Report a problemFND-2357452909
10HumanRandomized controlled trialEfficacy outcome
In untreated diabetes, low-dose exenatide improved insulin secretion rates when considered against plasma glucose and insulin sensitivity.
In plain wordsIn untreated diabetes, low-dose exenatide improved insulin secretion after accounting for blood sugar and insulin sensitivity.
Peptide
Exenatide (exendin-4)
Outcome
IncreaseAdjusted insulin secretion rate at low dose
Study
n: not reported in source
Outcome group
Glycemic control · Metabolic and weight
Studied dose
5 μg twice daily · 24 weeksAs given in this study (human).
Source sentences
Summary
However, when considered as a function of plasma glucose and insulin sensitivity, both doses of exenatide improved ISR proportionately to the improvement in plasma glucose.
1 context sentence(design, population, supporting numbers)
Summary · context
Seventy-nine subjects with previously untreated T2DM were studied before and after 24 weeks of treatment with one of the two doses of exenatide, 5- or 10-μg twice daily, or placebo.
Report a problemFND-2357452912
11HumanRandomized controlled trialEfficacy outcome
In untreated diabetes, high-dose exenatide improved insulin secretion rates when considered against plasma glucose and insulin sensitivity.
In plain wordsIn untreated diabetes, high-dose exenatide improved insulin secretion after accounting for blood sugar and insulin sensitivity.
Peptide
Exenatide (exendin-4)
Outcome
IncreaseAdjusted insulin secretion rate at high dose
Study
n: not reported in source
Outcome group
Glycemic control · Metabolic and weight
Studied dose
10 μg twice daily · 24 weeksAs given in this study (human).
Source sentences
Summary
However, when considered as a function of plasma glucose and insulin sensitivity, both doses of exenatide improved ISR proportionately to the improvement in plasma glucose.
1 context sentence(design, population, supporting numbers)
Summary · context
Seventy-nine subjects with previously untreated T2DM were studied before and after 24 weeks of treatment with one of the two doses of exenatide, 5- or 10-μg twice daily, or placebo.
Report a problemFND-2357452913
12HumanRandomized controlled trialEfficacy outcome
In untreated diabetes, high-dose exenatide was associated with significantly improved beta-cell glucose sensitivity.
In plain wordsIn untreated diabetes, high-dose exenatide was linked to improved insulin-producing cell sensitivity to glucose.
Peptide
Exenatide (exendin-4)
Outcome
IncreaseBeta-cell glucose sensitivity
Study
n: not reported in source
Outcome group
Glycemic control · Metabolic and weight
Studied dose
10 μg twice daily · 24 weeksAs given in this study (human).
Source sentences
Summary
The higher dose of exenatide was associated with a significant improvement in β-cell sensitivity to glucose.
1 context sentence(design, population, supporting numbers)
Summary · context
Seventy-nine subjects with previously untreated T2DM were studied before and after 24 weeks of treatment with one of the two doses of exenatide, 5- or 10-μg twice daily, or placebo.
Report a problemFND-2357452914

Studies that did not test the peptide alone2

In this study, Exenatide (exendin-4) was a lab tool or a carrier, part of a mix, or the subject of a lab method. These results are not evidence about taking Exenatide (exendin-4).

13HumanNot a test of Exenatide (exendin-4) aloneRandomized controlled trialEfficacy outcome
In untreated diabetes, all groups, including placebo and both exenatide doses, lost similar small amounts of weight.
In plain wordsIn untreated diabetes, weight decreased similarly in placebo and both exenatide dose groups.
Peptide
Exenatide (exendin-4)
Outcome
No significant changeBody weight
Study
n = 79
Comparator
Placebo
Outcome group
Body weight · Metabolic and weight
Source sentences
Summary
During the trial, all three groups lost similar, small but significant, amounts of weight.
1 context sentence(design, population, supporting numbers)
Summary · context
Seventy-nine subjects with previously untreated T2DM were studied before and after 24 weeks of treatment with one of the two doses of exenatide, 5- or 10-μg twice daily, or placebo.
In this study, Exenatide (exendin-4) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Exenatide (exendin-4).
Report a problemFND-2357452901
14HumanNot a test of Exenatide (exendin-4) aloneRandomized controlled trialEfficacy outcome
In untreated diabetes, OGTT plasma insulin did not differ before and after either exenatide or placebo treatment.
In plain wordsIn untreated diabetes, insulin during glucose testing did not change with either exenatide or placebo.
Peptide
Exenatide (exendin-4)
Outcome
No significant changeOGTT plasma insulin
Study
n = 79
Comparator
Placebo
Outcome group
Glycemic control · Metabolic and weight
Source sentences
Summary
Plasma insulin levels and ISR during the OGTT did not differ before or after treatment with exenatide or placebo.
1 context sentence(design, population, supporting numbers)
Summary · context
Seventy-nine subjects with previously untreated T2DM were studied before and after 24 weeks of treatment with one of the two doses of exenatide, 5- or 10-μg twice daily, or placebo.
In this study, Exenatide (exendin-4) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Exenatide (exendin-4).
Report a problemFND-2357452910

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Version 2Current
22 Oct 2026, 02:26 UTC
Study results updated
Version 1
21 Oct 2026, 18:59 UTC
First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.